Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

August 1, 2027

Study Completion Date

September 30, 2029

Conditions

Breast CancerCancer of the Breast

Interventions

DEVICE

DiviTum® TKa assay

-Determines serum enzymatic activity of TK1

OTHER

Study Care Plans

-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value

Trial Locations (1)

RECRUITING

Washington University School of Medicine, St Louis